PSMC will change its name to HLB innoVation at a shareholder meeting next month to emerge as the HLB Group’s key unit in developing CAR-T (chimeric antigen receptor-T cell) treatments.
 

Please refer to the following website for further details:  

https://www.koreabiomed.com/news/articleView.html?idxno=20534